ORAL LOSARTAN IN THE PREVENTION OF POST-ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PANCREATITIS | ||
| Journal of the Egyptian Society of Parasitology | ||
| Article 2, Volume 50, Issue 2, August 2020, Pages 228-234 PDF (687.23 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jesp.2020.113001 | ||
| Authors | ||
| YASMINE M. MASSOUD1; DOAA Z. ZAKY1; SHEREEN A. SALEH2; RAMY M. SALEM3; HOSSAM E. SALEM1 | ||
| 1Departments of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt | ||
| 2Internal Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt | ||
| 3Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt | ||
| Abstract | ||
| Generally speaking, acute pancreatitis is a dreadful complication of the endoscopic retro-grade cholangio-pancreatography (ERCP). But, losartan was suggested to prevent the post-ERCP acute pancreatitis. Thus, this study evaluated the use of oral losartan in prevention of the post-ERCP pancreatitis. The study was conducted on 50 patients who received 50mg of oral losartan one hour before ERCP (Study group), and another 50 patients who underwent ERCP without losartan prophylaxis (Control group). Serum amylase and lipase were measured before and after ERCP. The results showed that two patients of the study group and one patient of the control one developed post ERCP-pancreatitis in a total percent of 3%. The use of oral Losartan in a dose of 50mg an hour before the ERCP did not significantly decrease the incidence of pancreatitis. The ERCP duration was significantly longer among cases that developed pancreatitis in the study group. | ||
| Keywords | ||
| Egypt; Patients; Losartan; ARBs; ERCP; pancreatitis | ||
|
Statistics Article View: 186 PDF Download: 214 |
||
